The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.

Objective: .To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center.Method: .A triangular approach integratin...

Full description

Bibliographic Details
Published in:Journal of Affective Disorders Vol. 294; pp. 592 - 597
Main Authors: McIntyre, Roger S., Lipsitz, Orly, Lui, Leanna M.W., Rodrigues, Nelson B., Gill, Hartej, Nasri, Flora, Ling, Rui, Teopiz, Kayla M., Ho, Roger C., Subramaniapillai, Mehala, Kratiuk, Kevin, Mansur, Rodrigo B., Jones, Brett D.M., Lee, Yena, Rosenblat, Joshua D.
Format: research Journal Article
Published: Elsevier B.V. Nov2021
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152080159&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 152080159
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01650327
        3M9
      jtl: Journal of Affective Disorders
      issn: 01650327
      maglogo: N
    pubinfo:
      dt: Nov2021
      vid: 294
      pid: 1004
      pub: Elsevier B.V.
    artinfo:
      ui:
        152080159
        152080159
        NLM34332360
        152080159
        10.1016/j.jad.2021.07.035
        NLM34332360
        152080159
      ppf: 592
      ppct: 5
      formats:
      tig:
        atl: The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
      aug:
        au:
          McIntyre, Roger S.
          Lipsitz, Orly
          Lui, Leanna M.W.
          Rodrigues, Nelson B.
          Gill, Hartej
          Nasri, Flora
          Ling, Rui
          Teopiz, Kayla M.
          Ho, Roger C.
          Subramaniapillai, Mehala
          Kratiuk, Kevin
          Mansur, Rodrigo B.
          Jones, Brett D.M.
          Lee, Yena
          Rosenblat, Joshua D.
        affil: Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada
      sug:
        subj:
          Ketamine Therapeutic Use
          Bipolar Disorder Drug Therapy
          Depression Drug Therapy
          Adult
          Self Report
          Psychological Tests
          Human
          Comparative Studies
          Multicenter Studies
          Evaluation Research
          Validation Studies
          Scales
          Questionnaires
          Adult: 19-44 years
      ab: Objective: .To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center.Method: .A triangular approach integrating both anchor-based and distributive methods was used to identify meaningful change on the patient-reported Quick Inventory for Depressive Symptoms Self-Report 16-Item (QIDS-SR16) as associated with the Patient Global Impression - Severity (PGI-S). Both the QIDS-SR16 and the PGI-S are self-report measures, and were collected at five timepoints (timepoints were approximately 2-7 days apart).Results: .A total of 297 adults with treatment-resistant depression (TRD) as part of either DSM-5-defined MDD or BD were included. The MCT for the QIDS-SR16 revealed that a mean improvement of 3.38 points from baseline was comparable to a 1-point improvement on the PGI-S. Together with an examination of the probability density function, a 3.5-point change is a reasonable MCT (i.e., 1-point PGI-S improvement) for the QIDS-SR16. A 2-point symptomatic improvement on the QIDS-SR16 was associated with no change on the PGI-S.Conclusion: .A 3.5-point reduction in the QIDS-SR16 represents a MCT based on the PGI-S for adults with treatment-resistant MDD or BD receiving intravenous ketamine treatment at a community-based mood disorders center. These findings are limited by the post-hoc nature of this analysis and open-label case-series design. Measurement-based care decisions by patients, providers and clinicians, as well as cost/reimbursement decisions should include consideration of meaningful change along with conventional objective outcomes.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N